Skip to main
  1. Stocks
  2. Newamsterdam Pharma Co NV
  3. Forecast
NAMS

NAMS Stock Forecast & Price Target

NAMS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NewAmsterdam Pharma Co is supported by a lead asset, obicetrapib, that has repeatedly shown meaningful LDL-C reductions, a clean safety profile, and practical oral once-daily dosing, all of which address clear gaps left by statins and injectable PCSK9 inhibitors. The bull case is further strengthened by a large unmet need in cardiovascular disease, with up to 50% of U.S. patients not reaching cholesterol goals and 9–15% unable to tolerate statins, while management believes a 40% LDL lowering can translate into a 20% lower MACE risk and support a >90% powered outcomes trial. In addition, the company’s cash balance of about $643MM and expected support through PREVAIL results and initial U.S. launch reduce financing pressure, while ex-U.S. milestones of up to €817MM and double-digit royalties add meaningful long-term optionality.

Bears say

NewAmsterdam Pharma Co is viewed negatively because its value hinges on a binary PREVAIL interim analysis in 4Q26, where the weaker MACE-3 endpoint appears to be the real hurdle and the modeled probability of success is only about 25% to 40%, versus a more optimistic 50% earlier estimate. Even if obicetrapib succeeds, the company still faces substantial clinical, regulatory, reimbursement, and commercialization risks, while competing against statins, PCSK9s, and other large-pharma therapies in a crowded market. With no current products on market, escalating R&D and launch costs, and a composition-of-matter patent expiring in 2027, it may need additional capital and still struggle to prove durable, profitable demand.

NAMS has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Newamsterdam Pharma Co NV and is not a guaranteed prediction by Public.com or investment advice.

NAMS Analyst Forecast & Price Prediction

Get the latest NAMS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NAMS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Newamsterdam Pharma Co NV (NAMS) Forecast

Analysts have given NAMS a Buy based on their latest research and market trends.

According to 7 analysts, NAMS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Newamsterdam Pharma Co NV (NAMS)


NAMS Analyst Forecast & Price Prediction

Get the latest NAMS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NAMS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NAMS stock data and trends